Product Description
Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15192105/)
Mechanisms of Action: H1 Inverse Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Dominican Republic | Ecuador | France | Hong Kong | India | Indonesia | Ireland | Lebanon | Malta | Mexico | New Zealand | Pakistan | Peru | Portugal | South Africa | Spain | Taiwan | Turkey | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|